Get the Stockscreener App
14.07
2.02%
-0.29
Pre-market:
14.02
-0.05
-0.36%
Vor Biopharma Inc stock is traded at $14.07, with a volume of 1.91M.
It is down -2.02% in the last 24 hours and down -3.83% over the past month.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
See More
Previous Close:
$14.36
Open:
$14.695
24h Volume:
1.91M
Relative Volume:
1.84
Market Cap:
$762.40M
Revenue:
-
Net Income/Loss:
$-883.08M
P/E Ratio:
-0.0422
EPS:
-333.4782
Net Cash Flow:
$-150.65M
1W Performance:
+5.87%
1M Performance:
-3.83%
6M Performance:
+4.15%
1Y Performance:
+286.33%
1-Day Range:
$13.45
$15.00
1-Week Range:
$12.58
$15.00
52-Week Range:
$3.644
$65.80
Vor Biopharma Inc Stock (VOR) Company Profile
Name
Vor Biopharma Inc
Sector
Industry
Phone
617-655-6580
Address
500 BOYLSTON STREET, BOSTON
Compare VOR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
14.07 | 762.40M | 0 | -883.08M | -150.65M | -333.48 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-26 | Initiated | Jefferies | Buy |
| Mar-19-26 | Initiated | Wells Fargo | Overweight |
| Jan-09-26 | Initiated | Citigroup | Buy |
| Dec-17-25 | Initiated | TD Cowen | Buy |
| Dec-09-25 | Initiated | JP Morgan | Overweight |
| Nov-25-25 | Resumed | Wedbush | Neutral |
| Oct-15-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-24-25 | Upgrade | Stifel | Hold → Buy |
| Jun-30-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-26-22 | Initiated | Wedbush | Outperform |
| Apr-27-22 | Initiated | Goldman | Neutral |
| Dec-17-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-21 | Initiated | Robert W. Baird | Outperform |
| Dec-02-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Mar-25-21 | Initiated | B. Riley Securities | Buy |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Mar-03-21 | Initiated | Evercore ISI | Outperform |
| Mar-02-21 | Initiated | Goldman | Sell |
| Mar-02-21 | Initiated | Stifel | Buy |
View All
Vor Biopharma Inc Stock (VOR) Latest News
Vor Biopharma (VOR) Stock Analysis Report | Financials & Insights - Benzinga
[Form 4] Vor Biopharma Inc. Insider Trading Activity - Stock Titan
Vor Biopharma (VOR) director receives 53,283 stock options at $14.09 strike - Stock Titan
Vor Biopharma (VOR) grants Alexander Cumbo 56,345 stock options - Stock Titan
Vor Biopharma (NASDAQ: VOR) updates and wins approval for 2021 equity plan - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Vor Bio gains boost from telitacicept IgA nephropathy approval - TipRanks
Vor Bio (VOR) drug telitacicept gains China NMPA nods in IgAN and Sjögren’s - Stock Titan
Vor Bio (VOR) Secures Conditional Approval for Telitacicept in C - GuruFocus
Vor Biopharma Inc. and RemeGen Co., Ltd. Receives NMPA Conditional Approval For Telitacicept For The Treatment Of IgA Nephropathy In China - marketscreener.com
Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China - Yahoo Finance
Vor Biopharma (VOR) Slips Over 8% as Biotech Sentiment WeighsThematic ETF Flow - newsline.com
Vor Biopharma (VOR) Declines Over 8% as Biotech Sector Faces Headwinds; Key Support Levels TestedMomentum Factor - newsline.com
Vor Biopharma (VOR) Drops Over 8% as Shares Approach Key SupportMax Pain Level - newsline.com
GREAT POINT PARTNERS LLC's Vor Biopharma Inc(VOR) Holding History - GuruFocus
VOR Stock Chart | VOR BIOPHARMA INC (NASDAQ:VOR) - ChartMill
Vor Biopharma’s Phase 3 Sjögren’s Trial Puts Telitacicept on Investors’ Radar - TipRanks
VOR: Advancing telitacicept in global phase III trials for MG and Sjögren's, targeting major markets - TradingView
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biotech Vor Bio hands 61,050 options, 12,900 RSUs to new staff - Stock Titan
Vor Biopharma (VOR) price target decreased by 10.34% to 37.13 - MSN
Vor Biopharma (VOR) Stock Eases Slightly as Shares Hold Near Key Support ZoneSign of Strength - newsline.com
Autoimmune biotech Vor Bio to share update at 2026 Jefferies conference - Stock Titan
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference - marketscreener.com
Vor Biopharma Surges 5.46% as Buyers Defend Key Support Level (VOR)Undervalued Stocks - newsline.com
VOR Stock Price, Quote & Chart | VOR BIOPHARMA INC (NASDAQ:VOR) - ChartMill
VOR Q1 2026 Earnings: EPS Misses by Substantial Margin Amid Ongoing Pipeline DevelopmentGross Profit Margin - newsline.com
VOR Reiterated by HC Wainwright & Co. -- Price Target Maintained at $31 - GuruFocus
H.C. Wainwright Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $31 - Moomoo
Vor Biopharma Price Target Maintained With a $31.00/Share by HC Wainwright & Co. - Moomoo
Vor Biopharma Shares Skyrocket on Global Licensing Deal for Autoimmune Therapy - MSN
Vor Biopharma Inc.Common Stock (NQ: VOR - FinancialContent
Venrock group holds capped 9.99% stake in VOR (VOR) via pre-funded warrants - Stock Titan
Verve Capital amends position; holds 9.3% of VOR (NASDAQ: VOR) - Stock Titan
We're Not Very Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate - Moomoo
We're Hopeful That Vor Biopharma (NASDAQ:VOR) Will Use Its Cash Wisely - Yahoo Finance
Vor Biopharma: Enrollment on Track for Phase 3 UPSTREAM MG Trial of Telitacicept in Generalized Myasthenia Gravis Patients With Topline Results Anticipated in 1H27 >VOR - Moomoo
VOR Maintained by Wedbush -- Price Target Raised to $18.00 - GuruFocus
Wells Fargo Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Phase 3 IgA kidney drug telitacicept cuts protein loss 55% in China trial - Stock Titan
Vor Biopharma Inc. Q1 2026 Financial Results and Forward-Looking Statements – SEC 10-Q Report - Minichart
Vor Bio Q1 Net Loss Narrows - Moomoo
Earnings Flash (VOR) Vor Biopharma Posts Q1 Net Loss $5.11 a Share, vs. FactSet Est of $0.78 Loss - marketscreener.com
Earnings Flash (VOR) Vor Biopharma Posts Q1 Net Loss $5.11 a Share, Vs. FactSet Est of $0.78 Loss - Moomoo
Vor Biopharma Inc. 1Q 2026: Net loss $(219.6M), Diluted EPS $(5.11) — 10-Q Summary - TradingView
Vor Biopharma Q1 net loss widens - TradingView
Vor Biopharma (NASDAQ: VOR) Q1 2026 loss widens as telitacicept trials advance on $491.5M cash runway - Stock Titan
Vor Biopharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance
TradingKey - TradingKey
MSN Money - MSN
Vor Biopharma Inc Stock (VOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vor Biopharma Inc Stock (VOR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 17 '26 |
Sale |
16.28 |
458,411 |
7,462,931 |
2,739,208 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 20 '26 |
Sale |
15.77 |
171,963 |
2,711,857 |
2,567,245 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 13 '26 |
Sale |
16.15 |
530,610 |
8,569,352 |
3,404,998 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 14 '26 |
Sale |
15.97 |
153,735 |
2,455,148 |
3,251,263 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 15 '26 |
Sale |
16.01 |
53,644 |
858,840 |
3,197,619 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 08 '26 |
Sale |
16.48 |
484,104 |
7,977,786 |
4,071,637 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 09 '26 |
Sale |
16.59 |
135,201 |
2,242,985 |
3,936,436 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 10 '26 |
Sale |
15.75 |
828 |
13,041 |
3,935,608 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 06 '26 |
Sale |
16.59 |
589,257 |
9,777,898 |
4,555,741 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 02 '26 |
Sale |
18.23 |
260,000 |
4,741,066 |
5,144,998 |
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):